Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
View Patent ↗The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
1. A compound of formula:
wherein
Ar is selected from the group consisting of phenyl and phenyl substituted with from one to three substituents independently selected from the group consisting of halogen, loweralkyl, loweracyl, loweralkoxy, fluoroloweralkyl, fluoroloweralkoxy, formyl, cyano, benzyl, benzyloxy, phenyl, substituted phenyl, heteroaryl, heterocyclylalkyl and nitro;
X is selected from the group consisting of O, CH 2 , CF 2 , C═O, and CR 1a R 1b ;
R 1a and R 1b are selected from the group consisting of H and lower alkyl, or R 1a and R 1b taken together may form a 3-6 membered ring, which may optionally contain a heteroatom chosen from O, S, SO, SO 2 , and NR 10 ;
R 10 is selected separately in each occurrence from the group consisting of H and lower alkyl;
m is zero, 1 or 2;
n is 1 or 2;
p is 1;
Y is selected from H,H; O; and H,R 3 ;
R 3 is lower alkyl;
Z is (CH 2 ) 1-10 ; in which one or two (CH 2 ) may optionally be replaced by a —O—, —NR 10 —, —SO—, —S(O) 2 —, —C(═O)— or —C═O(NH)—, provided that said —O—, —NR 10 —, —SO—, —S(O) 2 —, —C(═O)— or —C═O(NH)— are not at the point of attachment to nitrogen and are separated by at least one —(CH 2 ) 2 —;
W is carboxyl or carboxamido; and
R 4 is selected from the group consisting of H and lower alkyl.
2. A compound according to claim 1 , wherein m is zero of formula:
wherein
R 1 or R 2 or are independently chosen from hydrogen, halogen, loweralkyl, loweracyl, loweralkoxy, fluoroloweralkyl, fluoroloweralkoxy, formyl, cyano, benzyl, benzyloxy, sulphonamide, amido, phenyl, substituted phenyl, heteroaryl, heterocyclylalkyl and nitro; or R 1 and R 2 taken together may form a 5-6 membered ring, which may optionally contain an oxygen.
3. A compound according to claim 2 , wherein
n is 1;
Z is (CH 2 ) 1-10 .
4. A compound according to claim 3 , wherein Y is H,H of formula:
wherein
R 1 is chosen from hydrogen, trifluoromethyl, (CF 3 ) 2 CHCH 2 —, methoxy, halogen, phenyl, cyano, and nitro;
X is chosen from —O— and —CH 2 —;
Z is (CH 2 ) 1-3 ; and
W is COOH.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound according to claim 1 .
6. A compound according to claim 2 , wherein n is 2 and Z is (CH 2 ) 1-10 .
7. A compound according to claim 6 , wherein Y is H,H of formula:
wherein
R 1 is chosen from hydrogen, trifluoromethyl, (CF 3 ) 2 CHCH 2 —, methoxy, halogen, phenyl, cyano, and nitro;
X is chosen from —O— and —CH 2 —;
Z is (CH 2 ) 1-3 ; and
W is COOH.
8. A compound according to claim 2 of formula:
wherein R 1 and R 2 are H; X is O; m is 0; Y is H,H; n is 1; Z is —(CH 2 ) 3 —, W is COOH, and the asterisk represents a chiral center having a (R) configuration.
9. A compound according to claim 2 of formula:
wherein R 1 and R 2 are H; X is O; m is 0; Y is H,H; n is 1; Z is —(CH 2 ) 3 —, W is COOH, and the asterisk represents a chiral center having a (S) configuration.
10. A compound according to claim 2 of formula:
wherein R 1 and R 2 are H; X is O; m is 0; Y is H,H; n is 1; Z is —(CH 2 ) 3 —, W is CONH 2 , and the asterisk represents a chiral center having a (S) configuration.
11. A compound according to claim 2 of formula:
wherein R 1 and R 2 are H; X is O; m is 0; Y is H,H; n is 1; Z is —(CH 2 ) 3 —, W is CONH 2 , and the asterisk represents a chiral center having a (R) configuration.